Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moFALMINA (levonorgestrel and ethinyl estradiol) by Xeltis is clinical pharmacology mode of action combination oral contraceptives prevent pregnancy primarily by suppressing ovulation. Approved for pregnancy. First approved in 2012.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Mode of Action Combination oral contraceptives prevent pregnancy primarily by suppressing ovulation. Pharmacokinetics Absorption No specific investigation of the absolute bioavailability of FALMINA (Levonorgestrel and Ethinyl Estradiol Tablets, USP) in humans has been…
Worked on FALMINA at Xeltis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects
Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)
AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol
Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo